CLOs on the Move


 
With its acquisition of Spyre Therapeutics, Aeglea is shifting its disease focus to inflammatory bowel disease (IBD). Spyre combines best-in-class antibody engineering, rational therapeutic combinations, and precision immunology approaches to maximize efficacy, safety, and convenience of treatments for IBD.
  • Number of Employees: 100-250
  • Annual Revenue: $10-50 Million
  • www.aeglea.com
  • 221 Crescent Street, Building 17 Suite 102B
    Waltham, MA USA 02453
  • Phone: 512.942.2935

Executives

Name Title Contact Details
Heidy King-Jones
Chief Legal Officer and Corporate Secretary Profile

Similar Companies

DMC

DMC is leading the low cost sustainable transformation of multiple product markets.

QuintilesIMS

Quintiles and IMSHealth have merged together to form the new QuintilesIMS. Each wanting to bring something new to customers, we deliver integrated information and technology solutions to drive healthcare forward. QuintilesIMS has approximately 50,000 employees conducting operations in more than 100 countries, dedicated to helping our clients improve their clinical, scientific and commercial results. As a global leader in protecting individual patient privacy, QuintilesIMS uses healthcare data to deliver critical, real-world disease and treatment insights.

Anthos Therapeutics

Anthos Therapeutics is a clinical-stage biopharmaceutical company focused on the development and commercialization of genetically and pharmacologically validated innovative therapies to advance care for people living with cardiovascular and metabolic (CVM) diseases. Anthos Therapeutics aims to combine the agility of a biotech with the rigor of a large pharmaceutical company. Anthos Therapeutics was launched by Blackstone Life Sciences in 2019.

Mendel Biotechnology

Mendel Biotechnology is one of the leading companies in the Healthcare, Pharmaceuticals, & Biotech sector.

Nautilus Environmental

Nautilus Environmental LLP is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.